Nanotherapy for AMD

Article

The use of green gold nanoparticles may have a place in the therapy of cancer and ophthalmic diseases, according to a study presented at this year's meeting of the Association for Research in Vision & Ophthalmology (ARVO).

The use of green gold nanoparticles may have a place in the therapy of cancer and ophthalmic diseases, according to a study presented at this year's meeting of the Association for Research in Vision & Ophthalmology (ARVO). Kattesh Katti, PhD, from Nanotechnology, Physics, and Radiology, University of Missouri, Columbia, US, who conducted the study, said that this was because of the affinity of the gold nanoparticles for leaky vasculature.

"The nanoparticles are focused and given a sense of direction so that, when injected into the tumours, they can provide morphologic information and possible directions for new therapeutic modalities," Dr Katti said.

The level of amplification of the therapeutic payload that the use of gold nanoparticles (with about 200 000 atoms) provides is not possible with conventional therapy, he said, using bevacizumab (Avastin; Genentech) as an example. "Super-Avastin" would have hundreds of units of bevacizumab in one particle: in age-related macular degeneration (AMD), a potent dose of a drug such as bevacizumab might allow intraperitoneal injections rather than invasive intraocular injections. In rats, this therapy has shown 80–95% blood vessel shrinkage, according to Dr Katti, a figure that was corroborated histologically.

"Nanoparticles . . . have an affinity for leaky vasculature in AMD and cancer, and there is a high affinity of biocompatible gold nanoparticles toward the vasculature [that] can be used for site-specific delivery and localization," Dr Katti said. "In addition, gold nanoparticles carry substantially increased therapeutic payloads compared with conventional therapy and they provide opportunities for designing new pharmaceuticals for treating cancer, AMD, and related diseases."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.